Keene & Associates Inc. Makes New $539,000 Investment in Royalty Pharma plc (NASDAQ:RPRX)

Keene & Associates Inc. purchased a new position in shares of Royalty Pharma plc (NASDAQ:RPRX) in the third quarter, according to its most recent filing with the SEC. The firm purchased 19,050 shares of the biopharmaceutical company’s stock, valued at approximately $539,000.

Other large investors have also recently bought and sold shares of the company. Versant Capital Management Inc grew its holdings in Royalty Pharma by 5,215.0% during the 2nd quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 1,043 shares during the period. Gladius Capital Management LP acquired a new stake in shares of Royalty Pharma in the 2nd quarter valued at about $32,000. Blue Trust Inc. grew its stake in shares of Royalty Pharma by 362.7% in the 3rd quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 943 shares during the period. Fidelis Capital Partners LLC acquired a new stake in shares of Royalty Pharma in the 1st quarter valued at about $46,000. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Royalty Pharma by 32.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 655 shares during the period. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Morgan Stanley lifted their price target on Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a research note on Thursday, July 11th. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, September 17th. Finally, The Goldman Sachs Group lifted their price target on Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Royalty Pharma Price Performance

Royalty Pharma stock opened at $27.36 on Thursday. Royalty Pharma plc has a 52 week low of $25.20 and a 52 week high of $31.66. The company’s 50 day moving average price is $28.02 and its two-hundred day moving average price is $27.65. The company has a quick ratio of 9.35, a current ratio of 9.35 and a debt-to-equity ratio of 0.78. The stock has a market cap of $16.24 billion, a P/E ratio of 24.21, a P/E/G ratio of 4.12 and a beta of 0.46.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.95 by $0.01. Royalty Pharma had a net margin of 30.08% and a return on equity of 23.61%. The firm had revenue of $537.00 million for the quarter, compared to analysts’ expectations of $600.83 million. During the same quarter last year, the firm earned $0.85 EPS. On average, equities analysts predict that Royalty Pharma plc will post 4.05 earnings per share for the current year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a $0.21 dividend. The ex-dividend date is Friday, November 15th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.07%. Royalty Pharma’s dividend payout ratio (DPR) is presently 74.34%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.